Comparison of the Effects of Sugammadex and Neostigmine on Early Extubation, Intensive Care Unit Admission and Length of Stay, and Hospital Costs in Adult Cranial Surgery

May 15, 2025 updated by: Naime Yalçın, Kanuni Sultan Suleyman Training and Research Hospital
The aim of this study was to retrospectively investigate the effects of sugammadex or neostigmine, which are routinely used after the completion of surgery to antagonize (reverse) neuromuscular blockade in adult patients undergoing cranial surgery under general anesthesia, on early extubation in the operating room, intensive care unit admission and length of stay, length of hospital stay, and hospital costs.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

112

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • İstanbul, Turkey
        • Kanuni Sultan Suleyman Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Among the patients who underwent cranial surgery under sevoflurane anesthesia and whose neuromuscular blockade was provided with rocuronium, the patients whose neuromuscular blockade was antagonized with neostigmine or sugammadex and who were admitted to the intensive care unit postoperatively were evaluated.

Description

Inclusion Criteria:

  • Patients from the American Society of Anesthesiology (ASA) I-II-III group,
  • over the age of 18,
  • who underwent elective surgery,
  • underwent general anesthesia with sevoflurane anesthesia from volatile anesthetics,
  • used rocuronium as a neuromuscular blocking agent

Exclusion Criteria:

  • Patients aged 18 and under,
  • ASA IV and above,
  • who underwent surgery under emergency conditions,
  • who have incomplete follow-up form records and electronic media data,
  • who were taken to the intensive care unit without neuromuscular blockade antagonism due to long surgery,
  • who were treated with a neuromuscular blocking agent other than rocuronium,
  • who were treated with a volatile anesthetic other than sevoflurane or with total intravenous anesthesia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group Neostigmine
Group Sugammadex

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The amount of cost in the hospital process
Time Frame: through study completion, an average of 3 month
through study completion, an average of 3 month
Length of stay in the intensive care unit
Time Frame: through study completion, an average of 3 month
through study completion, an average of 3 month
Early extubation rate after two different neuromuscular blocking antagonist drugs
Time Frame: through study completion, an average of 3 month
through study completion, an average of 3 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2021

Primary Completion (Actual)

July 31, 2021

Study Completion (Actual)

July 31, 2021

Study Registration Dates

First Submitted

May 9, 2025

First Submitted That Met QC Criteria

May 15, 2025

First Posted (Actual)

May 23, 2025

Study Record Updates

Last Update Posted (Actual)

May 23, 2025

Last Update Submitted That Met QC Criteria

May 15, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • KAEK/2021.04.116

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Extubation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe